Combination of Talquetamab and Pomalidomide in relapse-refractory high-risk Multiple Myeloma, including refractoriness to Mezigdomide
International Journal of Cancer Care and Delivery · 2025
DOI: 10.53876/001a.129573 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Cancer Care and Delivery, 2025. Verfasst von Haleema Sadia Adil und 5 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-SA 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Adil, H. S., Subramanian, S., Anwer, F., Bevacqua, J., Williams, L., & Raza, S. (2025). Combination of Talquetamab and Pomalidomide in relapse-refractory high-risk Multiple Myeloma, including refractoriness to Mezigdomide. International Journal of Cancer Care and Delivery. https://doi.org/10.53876/001a.129573
Vancouver
Adil HS, Subramanian S, Anwer F, Bevacqua J, Williams L, Raza S. Combination of Talquetamab and Pomalidomide in relapse-refractory high-risk Multiple Myeloma, including refractoriness to Mezigdomide. International Journal of Cancer Care and Delivery. 2025. doi:10.53876/001a.129573
BibTeX
@article{Adil2025,
author = {Adil, Haleema Sadia and Subramanian, Siriram and Anwer, Faiz and Bevacqua, Julie and Williams, Louis and Raza, Shahzad},
title = {Combination of Talquetamab and Pomalidomide in relapse-refractory high-risk Multiple Myeloma, including refractoriness to Mezigdomide},
journal = {International Journal of Cancer Care and Delivery},
year = {2025},
doi = {10.53876/001a.129573}
}
EUVIMED